This phase II clinical trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia. Monoclonal antibodies, such as pembrolizumab, may strengthen the immune system and help it to target remaining cancer cells.